Establishment of a new human myeloma cell line, KMS-18, having t(4;14)(p16.3;q32.3) derived from a case phenotypically transformed from Ig A-λ to BJP-λ, and associated with hyperammonemia

International Journal of Oncology

Volumn 12, Issue 3, 1998, Pages 545-552

  Otsuki, Takemi ^a   Nakazawa, Naozo ^b   Taniwaki, Masafumi ^b   Yamada, Osamu ^a   Sakaguchi, Haruko ^a   Wada, Hideho ^a   Yawata, Yoshihito ^a   Ueki, Ayako ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cell line KMS 18; Fibroblast growth factor receptor 3; Hyperammonemia; Myeloma; Translocation

Indexed keywords

AMMONIA; BENCE JONES PROTEIN; IMMUNOGLOBULIN A;

ADULT; AMMONIA FORMATION; ARTICLE; CANCER CELL CULTURE; CASE REPORT; CELL TRANSFORMATION; CHROMOSOME 10Q; CHROMOSOME 14Q; CHROMOSOME 17P; CHROMOSOME 1Q; CHROMOSOME 4P; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HYPERAMMONEMIA; KARYOTYPE; LEUKEMIA CELL; LIVER CELL CARCINOMA; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

AMMONIA; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CELL CULTURE TECHNIQUES; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; HEMATOLOGIC NEOPLASMS; HERPESVIRUS 4, HUMAN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYCOPLASMA; PHENOTYPE; POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0031882279     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Togawa A, Inoue N, Miyamoto K, Hyodo H and Namba M: Establishment and characterization of a human myeloma cell line (KMM-1). Int J Cancer 29: 195-500, 1982.
2. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M and Namba M: Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol 73: 199-204, 1989.
3. Ohtsuki T, Nishitani K, Hatamochi A, Yawata Y and Namba M: Analysis of methylation in the c-MYC gene in five human myeloma cell lines. Br J Haematol 77:172-179, 1991.
4. Namba M, Ohtsuki T, Mori M, Togawa A, Wada H, Sugihara T, Yawata Y and Kimoto T: Establishment of five human myeloma cell lines. In Vitro Cell Dev Biol 25: 723-729, 1989.
5. Shirato L, Otsuki T, Yamada O, Namba M, Nakajima H, Nozawa Y, Ueki A and Yawata Y: Down regulation of protein kinase C during growth enhancement induced by interleukin-6 on a human myeloma cell line, KMS-11. Cancer Lett 107: 131-136, 1996.
6. Seto M, Yamamoto K, Iida S, Akao Y, Utsumi KR, Kubonishi I, Miyoshi I, Ohtsuki T, Yawata Y, Namba M, Arnold A, Takahashi T and Ueda R: Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene 7: 1401-1406, 1992.
7. Holt JT, Morton CC, Nienhuis AW and Leder P: Molecular mechanisms of hematological neoplasms. In: The Molecular Basis of Blood Diseases. Stamatoyannopoulos G. Nienhuis AW, Leder P and Majerus PW (eds.) W.B, Saunders, Philadelphia, pp347-376, 1987.
8. Gauwerky CE and Croce CM: Molecular genetics and cytogenetics of hematopoietic malignancies. In: The Molecular Basis of Cancer. Mendelsohn J, Howley PM, Israel MA and Liotta LA (eds.) W.B. Saunders, Philadelphia, pp18-37, 1995.
9. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F and Facon T: Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 85:2490-2497, 1995.
10. Sawyer JR, Waldron JA, Jagannath S and Barlogie B: Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41-49, 1995.
11. Taniwaki M, Nishida K, Takashima T, Nakagawa H, Fujii H, Tamaki T, Shimazaki C, Horiike S, Misawa S, Abe T, Kashima K: Non-random chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84: 2283-2290, 1994.
12. Sawyer JR, Waldron JA, Jagannath S and Barlogie B: Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41-49, 1995.
13. Fiedler W, Weh HJ and Hossfeld DK: Comparison of chromosome analysis and BCL-1 rearrangement in a series of patients with multiple myeloma. Br J Haematol 81: 58-61, 1992.
14. Meeus P, Stul MS, Mecucci C, Cassiman JJ and Van den Berghe H: Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma. Cancer Genet Cytogenet 83: 25-27, 1995.
15. Taniwaki M, Nishida K, Ueda Y and Takashima T: Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. Leuk Lymphoma 21:25-30, 1996.
16. Ueda Y, Matsuda F, Misawa S and Taniwaki M: Tumor-specific rearrangements of the immunoglobulin heavy-chain gene in B-cell non-Hodgkin's lymphoma detected by in situ hybridization. Blood 87: 292-298, 1996.
17. Taniwaki M, Silverman GA, Nishida K, Horiike S, Misawa S, Shimazaki C, Miura I, Nagai M, Abe M, Fukuhara S, and Kashima K: Translocations and amplification of the BCL2 gene are detected in interphase nuclei of non-Hodgkin's lymphoma by in situ hybridization with yeast artificial chromosome clones. Blood 86: 1481-1486, 1995.
18. Nakai H, Taniwaki M, Tanaka S, Nishigaki H, Nakagawa H, Misawa S and Kashima K: Characterization of a 14q+ marker chromosome in Philadelphia chromosome positive acute lymphoblastic leukemia by DNA analysis and fluorescence in situ hybridization. Cancer Genet Cytogenet 81: 83-91, 1995.
19. Calasanz MJ, Cigudosa JC, Odero MD, Ferreira C, Ardanaz MT, Fraile A, Carrasco JL, Sole F, Cuesta B and Gullon A: Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosom Cancer 18: 84-93, 1997.
20. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL and Kuehl WM: Promiscuous translocation into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 93: 13931-13936, 1996.
21. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM and Bergsagel PL: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16: 260-264, 1997.
22. Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT and Neri A: A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood (In press).
23. Matsuzaki H, Uchiba M, Yoshimura K, Yoshida M, Akahoshi Y, Okazaki K and Takatsuki K: Hyperammonemia in multiple myeloma. Acta Haematol 84: 130-134, 1990.
24. Matsuzaki H, Matsuno F, Yoshida M, Hata H, Okazaki K and Takatsuki K: Human myeloma cell line (KHM-4) established from a patient with multiple myeloma associated with hyperammonemia. Internal Med 31: 339-343, 1992.
25. Matsuzaki H, Hata H, Sonoki T, Matsuno F, Kuribayashi N, Yoshida M, Nagasaki A, Murata H, Fujiyama S and Takatsuki K: Serum amino acid disturbance in multiple myeloma with hyperammonemia. Int J Hematol 61:131-137, 1995.
26. Caminal L, Castellanos E, Mateos V, Astudillo A, Moreno C and Dieguez MA: Hyperammonaemic encephalopathy as the presenting feature of IgD multiple myeloma. J Intern Med 233: 277-279, 1993.
27. Ohmoto A, Kohno M, Yasukawa K and Matsuyama R: Massive ascites as an initial sign, plasmacytoma of the cervical supine, and hyperammonemic consciousness disturbance in a patient with biclonal type multiple myeloma. Jpn J Clin Hematol 37: 346-351, 1996.
28. Takimoto Y, Imanaka F, Hayashi Y and Morioka S: A patient with ammonia-producing multiple myeloma showing hyper-ammonemic encephalopathy. Leukemia 10: 918-919, 1996.
29. Kawano F, Tsukamoto A, Satoh M, Sanada I, Shido T, Miura K, Murakami T, Kaneko H, Takeya M, Matsuzaki H and Takatsuki K: Non-secretory primary plasma cell leukemia with hyperammonemia. Jpn J Clin Hematol 32:399-403, 1991.
30. Tsunoda S, Sasaki R, Miwa A, Sakurabayashi I and Miura Y: Coma, hyperviscosity syndrome, hyperammonemia and myelofibrosis in a patient with IgG, λ-type multiple myeloma. Jpn J Clin Hematol 30: 361-365, 1989.
31. Nakahashi E, Kuribayashi N, Tsuji N, Kawaguchi T, Hata H, Matsuzaki H, Shimizu K and Takatsuki K: Primary plasma cell leukemia complicated with high-output cardiac failure and hyperammonemia. Jpn J Clin Hematol 35:756-760, 1994.
32. Otsuki T, Kumar S, Ensoli B, Kingma DW, Yano T, Stetler-Stevenson M, Jaffe ES and Raffeld M: Detection of HHV-8/KSHV DNA sequences in AIDS-associated extranodal lymphoid malignancies. Leukemia 10: 1358-1362, 1996.
33. Chen TR: In situ detection of mycoplasma contamination in cell culture by fluorescent Hoechst 33258 stain. Exp Cell Res 104: 255-262, 1977.
34. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 55: 1436-1440, 1995.
35. Ikeuchi T and Sasaki M: Accumulation of early mitotic cells in ethidium bromide-treated human lymphocyte cultures. Proc Jpn Acad 55: 15-18, 1979.
36. Oken MM: Multiple myeloma: prognosis and standard treatment. Cancer Invest 15: 57-64, 1997.
37. Bjorkstrand B: Multiple myeloma, high-dose treatment and autologous stem cell transplantation-current status. Med Oncol 13: 23-30, 1996.
38. Zulian GB: Multiple myeloma: clinical evaluation of plasma cell lymphoproliferative disorders and initial management. Semin Hematol 34 (Suppl 1): 239, 1997.
39. Blade J, San-Miguel JF, Fontanillas M, Alcala A, Maldonado J, Garcia-Conde J, Conde E, Conzalez-Brito G, Moro MJ, Escudero ML, Trujillo J, Pascual A, Rozman C, Estape J and Montserrat E: Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol 14:2167-2173, 1996.
40. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C and Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996.
41. Grignani G, Gobbi PG, Formisano R, Pieresca C, Ucci G, Brugnatelli S, Riccardi A and Ascari E: A prognostic index for multiple myeloma. Br J Cancer. 73: 1101-1107, 1996.
42. Epstein J, Hoover R, Kornbluth J and Barlogie B: Biological aspects of multiple myeloma. Bailliere Clin Haematol 8:721-734, 1995.
43. Barlogie B, Hoover R and Epstein J: Multiple myeloma: recent developments in molecular and cellular biology. Curr Top Microbiol Immunol 194: 37-41, 1995.
44. Bornkamm GW, Polack A, Eick D: c-myc deregulation by chromosomal translocation in Burkitt's lymphoma. In: Cellular Oncogene Activation, Klein G (ed.) Marcel Dekker, New York, pp223-274, 1988.
45. Raffeld M, Sander CA, Yano T and Jaffe ES: Mantle cell lymphoma: an update. Leuk Lymphoma 8:161-166, 1992.
46. Argatoff LH, Connors JM, Klasa RJ, Horsman DE and Gascoyne RD: Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 89: 2067-2078, 1997.
47. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL and Korsmeyer SJ: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41: 899-906, 1985.
48. Cleary ML and Sklar J: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82: 7439-7443, 1985.
49. Johnson DE and Williams LT: Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60: 1-41, 1993.
50. Basilico C and Moscatelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 59: 115-165, 1992.
51. Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH and Wasmuth JJ: Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9: 321-328, 1995.
52. Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST and Wasmuth JJ: Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78: 335-342, 1994.
53. Muenke M and Schell U: Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 11: 308-313, 1995.
54. Matsuno F, Matsuzaki H, Akahoshi Y, Yoshida M, Hata H, Takiguchi M, Takatsuki K and Mori M: A novel ornithine transcarbamylase present in mycoplasma-infected myeloma cells. Enzyme Protein 47: 57-64, 1993.